Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  BioSig Technologies Inc    

BIOSIG TECHNOLOGIES INC
My previous session
Most popular
  Report  
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Unregistered Sales of Equity Securities

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/08/2018 | 10:05am CEST

BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02Unregistered Sales of Equity Securities.

On December 29, 2017 and January 5, 2018, BioSig Technologies, Inc. (the “Company”) consummated an eleventh and twelfth closing, respectively, under the Unit Purchase Agreement, dated April 6, 2017 (the “Purchase Agreement”), by and among the Company and certain accredited investors (the “December-January Investors”), to which the Company issued an aggregate of 660,668 units (the “Units”), in exchange for aggregate consideration of $991,001. Each Unit consists of one share (the “Investor Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and a warrant to purchase one half of one share of Common Stock, exercisable at a price of $1.50 per share (the “Investor Warrants”), at a per Unit price of $1.50. In addition, in connection with the eleventh and twelfth closings, each December-January Investor became party to that certain Registration Rights Agreement, dated as of April 6, 2017.

As previously reported in the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission on April 6, 2017, July 6, 2017, July 19, 2017, August 23, 2017, September 26, 2017, October 17, 2017 and November 13, 2017, the Company: (i) consummated the first closing under the Purchase Agreement on April 6, 2017, to which the Company issued to the initial investors (the “Initial Investors”) an aggregate of 426,667 Units in exchange for aggregate consideration of $640,000; (ii) consummated the second, third, fourth and fifth closings under the Purchase Agreement on April 17, 2017, May 5, 2017, June 20, 2017 and June 30, 2017, respectively, to which the Company issued to certain additional investors (the “April-June Investors”) an aggregate of 399,933 Units, in exchange for aggregate consideration of $599,898; (iii) consummated the sixth closing under the Purchase Agreement on July 13, 2017, to which the Company issued to certain additional investors (the “July Investors”) an aggregate of 267,002 Units, in exchange for aggregate consideration of $400,500; (iv) consummated the seventh closing under the Purchase Agreement on August 18, 2017, to which the Company issued to certain additional investors (the “August Investors”); (v) consummated the eighth closing under the Purchase Agreement on September 20, 2017, to which the Company issued to certain additional investors (the “September Investors”) an aggregate of 103,334 Units, in exchange for aggregate consideration of $155,000; (vi) consummated the ninth closing under the Purchase Agreement on October 11, 2017, to which the Company issued to certain additional investors (the “October Investors”) an aggregate of 386,667 Units in exchange for aggregate consideration of $580,000; and (vii) consummated the tenth closing under the Purchase Agreement on November 6, 2017, to which the Company issued to certain additional investors (the “November Investors” and collectively with the December-January Investors, the September Investors, the August Investors, the July Investors, the April-June Investors and the Initial Investors, the “Investors”) an aggregate of 413,336 Units in exchange for aggregate consideration of $620,002.

The Units, Investor Shares and Investor Warrants issued and sold to the Investors were not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act, provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act. Each Investor represented that it was an accredited investor (as defined by Rule 501 under the Securities Act).

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 2, 2018, the Company promoted Steve Chaussy, its current Chief Financial Officer, to a full time position. In connection with Mr. Chaussy transitioning to full time from his previous part time position, the Company increased his annual compensation from $160,000 to $235,000. Mr. Chaussy continues to be eligible to receive performance bonuses payable in either cash or equity securities of the Company at the discretion of the Company’s compensation committee.

About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.

The post BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Unregistered Sales of Equity Securities appeared first on Market Exclusive.

© Market Exclusive 2018, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOSIG TECHNOLOGIES INC
09/25BIOSIG TECHNOLOGIES : Retains Gilmartin Group for Investor Relations
AQ
09/19BioSig Technologies to Commence Trading on the Nasdaq
GL
09/11BioSig Technologies Issues Shareholder Letter
GL
09/11BIOSIG TECHNOLOGIES : Announces 1-for-2.5 Reverse Stock Split for Pending Uplist..
AQ
09/10BIOSIG TECHNOLOGIES, INC. : Material Modification to Rights of Security Holders,..
AQ
09/10BioSig Technologies, Inc. Announces 1-for-2.5 Reverse Stock Split for Pending..
GL
08/24BIOSIG TECHNOLOGIES, INC. : Other Events (form 8-K)
AQ
08/23BIOSIG TECHNOLOGIES, INC. : Unregistered Sale of Equity Securities (form 8-K)
AQ
08/22BioSig Technologies to Present at the MicroCap Leadership Summit
GL
08/21BIOSIG TECHNOLOGIES : Appoints Johnson & Johnson Veteran Amy Scott
AQ
More news
News from SeekingAlpha
09/10BIOSIG TECH REVERSE SPITS SHARES 1 : 2.5 
08/18YOUR DAILY PHARMA SCOOP : Catalyst Positive, JNJ Succeeds, Blue Chips Support Ti.. 
08/17BioSig Tech closes $6M equity offering 
08/15BioSig Tech up 5% on FDA approval for ECG data management system 
04/14DAILY INSIDER RATINGS ROUND UP 4/12/ : Conn, opk, bsgm 
Financials ($)
Sales 2018 -
EBIT 2018 -15,3 M
Net income 2018 -15,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 28,4x
Capitalization 71,0 M
Chart BIOSIG TECHNOLOGIES INC
Duration : Period :
BioSig Technologies Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 10,6 $
Spread / Average Target 128%
EPS Revisions
Managers
NameTitle
Kenneth L. Londoner Executive Chairman & Chief Executive Officer
Steven Chaussy Chief Financial Officer
Roy T. Tanaka Independent Director
Seth H. Z. Fischer Independent Director
Patrick Gallagher Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
0
THERMO FISHER SCIENTIFIC21.87%94 516
DANAHER CORPORATION9.88%73 446
INTUITIVE SURGICAL42.29%61 755
BOSTON SCIENTIFIC CORPORATION46.95%52 551
ILLUMINA47.23%48 357